Apr 18, 2022 8:30 am EDT Heat Biologics’ Scorpion Subsidiary Announces Planned Development of New Kansas Commercial/Biodefense Biomanufacturing Facility
Apr 14, 2022 12:35 pm EDT Heat Biologics’ Announces Planned Investor and Media Livestream Event to Discuss Latest Developments
Mar 23, 2022 8:30 am EDT Heat Biologics Announces Appointment of Greg Burel, Former Director of the Strategic National Stockpile, to its Biothreat Advisory Board and as Senior Advisor to the Company
Jan 31, 2022 7:30 am EST Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, Its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human Services
Jan 12, 2022 8:00 am EST Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110
Nov 30, 2021 7:30 am EST Heat Biologics Unveils RapidVax®, A Novel Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological Threats